BioSpace News Archive

Hansa Biopharma AB “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced the release of the Annual Report 2022.

Molecure S.A. a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces full year results for the period ended 31 December 2022.

Takeda announced that its Board of Directors decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023.

Selvita S.A. one of the largest CRO companies in Europe has published a full-year report for 2022.

On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. released its annual financial results for 2022.

NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of its scientific advisory board, to support and steer its R&D programmes to develop novel small molecule therapies for the treatment of neurodegenerative disorders.

Confo Therapeutics announced that it has entered a collaboration agreement with Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority.

Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new analyses on amyloid-related imaging abnormalities with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life, from the results of Eisai’s Phase 3 Clarity AD study of lecanemab, an anti-amyloid-β protofibril* antibody, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases annual meeting AD/PD™.

Everest Medicines announced its financial results for the full year ended December 31, 2022, along with a corporate update.